Redwood Investment Management LLC Takes $1.17 Million Position in United Therapeutics Corporation $UTHR

Redwood Investment Management LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,154 shares of the biotechnology company’s stock, valued at approximately $1,167,000.

A number of other hedge funds have also recently added to or reduced their stakes in UTHR. Arjuna Capital increased its position in United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 18 shares during the period. Sage Rhino Capital LLC lifted its holdings in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC lifted its holdings in shares of United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 24 shares during the period. Meeder Advisory Services Inc. boosted its stake in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after buying an additional 26 shares in the last quarter. Finally, Independent Advisor Alliance boosted its stake in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 27 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on UTHR. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Trading Down 0.4%

NASDAQ:UTHR opened at $516.68 on Thursday. The company has a market capitalization of $22.16 billion, a P/E ratio of 18.49, a price-to-earnings-growth ratio of 1.76 and a beta of 0.59. The firm has a 50-day moving average price of $531.06 and a two-hundred day moving average price of $538.56. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.41 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total value of $5,202,295.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,185,323.93. This represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,311,581.28. This trade represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 424,075 shares of company stock valued at $227,683,710 over the last 90 days. Insiders own 8.60% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.